Literature DB >> 6638546

The effect of halothane anesthesia on myocardial necrosis, hemodynamic performance, and regional myocardial blood flow in dogs following coronary artery occlusion.

R F Davis, L W DeBoer, R E Rude, E Lowenstein, P R Maroko.   

Abstract

The effect of halothane anesthesia on myocardial necrosis resulting from coronary artery ligation was examined in 28 anesthetized mongrel dogs. In 18 dogs, the left anterior descending coronary artery (LAD) was ligated immediately proximal to the first apical diagonal branch, and 1 h later the dogs were assigned randomly either to receive halothane, 0.5-1.0% inspired in room air for 12 h (n = 10) or to awaken without further intervention (control, n = 8). Infarct size was measured by staining the myocardium with triphenyl tetrazolium chloride 24 h after LAD ligation. Infarct size in halothane-treated dogs was 17.8 +/- 2.0% of the left ventricle, compared with 27.3 +/- 3.3% in control dogs (P less than 0.05). Myocardial salvage was present transmurally but was greatest in epicardial regions. In 10 additional dogs, hemodynamic variables (heart rate, arterial pressure, left ventricular end-diastolic pressure, peak left ventricular dP/dt, tension-time index, and rate-pressure product) were measured or calculated, and radionuclide-labeled microspheres were injected for measurement of cardiac output and regional myocardial blood flow (RMBF). Thirty minutes after LAD ligation and after initial hemodynamic measurements and microsphere injection, these dogs were assigned randomly to receive either halothane, 1.0%, inspired in room air (n = 5) or no intervention (control, n = 5). After 15 min of halothane inhalation (45 min after LAD ligation in control dogs), measurements were repeated. Halothane inhalation reduced heart rate, arterial pressure, and indexes of left ventricular contractile and pump performance. During halothane treatment, RMBF declined in normal myocardium but not in ischemic regions, while neither normal nor ischemic zone RMBF changed in control dogs. Systemic vascular resistance was unchanged in either group. Thus, halothane was associated with a 35% smaller myocardial infarct, transmural myocardial salvage, reduced heart rate, reduced left ventricular contractile and pump performance, reduced RMBF to nonischemic regions, and unchanged RMBF in the ischemic myocardium.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6638546     DOI: 10.1097/00000542-198311000-00007

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

Review 1.  Signaling and cellular mechanisms in cardiac protection by ischemic and pharmacological preconditioning.

Authors:  Michael Zaugg; Marcus C Schaub
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

Review 2.  [Cardioprotection in cardiac surgical patients : Everything good comes from the heart].

Authors:  C Stoppe; P Meybohm; M Coburn; A Goetzenich
Journal:  Anaesthesist       Date:  2016-03       Impact factor: 1.041

3.  Myocardial ischaemic/reperfusion injury in the anaesthetized rabbit: comparative effects of halothane and isoflurane.

Authors:  J Dolman; D V Godin
Journal:  Can Anaesth Soc J       Date:  1986-07

4.  Repeated remote ischemic preconditioning and isoflurane anesthesia in an experimental model of renal ischemia-reperfusion injury.

Authors:  Theo P Menting; Mehmet Ergun; Moira H D Bruintjes; Kimberley E Wever; Roger M L M Lomme; Harry van Goor; Michiel C Warlé
Journal:  BMC Anesthesiol       Date:  2017-01-28       Impact factor: 2.217

Review 5.  Peri-operative anaesthetic myocardial preconditioning and protection - cellular mechanisms and clinical relevance in cardiac anaesthesia.

Authors:  G Kunst; A A Klein
Journal:  Anaesthesia       Date:  2015-04       Impact factor: 6.955

6.  Insulin preconditioning elevates p-Akt and cardiac contractility after reperfusion in the isolated ischemic rat heart.

Authors:  Tamaki Sato; Hiroaki Sato; Takeshi Oguchi; Hisashi Fukushima; George Carvalho; Ralph Lattermann; Takashi Matsukawa; Thomas Schricker
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.